Sign up USA
Proactive Investors - Run By Investors For Investors

Biogen Idec wins FDA approval for MS drug label change

Biogen Idec wins FDA approval for MS drug label change

Biogen Idec (NASDAQ:BIIB) announced late Friday that the US FDA has approved a change to the safety information on the label for its Tysabri drug, intended for the treatment of multiple sclerosis (MS).

The new label identifies a risk factor that promotes progressive multifocal leukoecephalopathy (PML), a rare, but serious brain infection. Patients receiving Tysabri who have anti-JCV antibodies possess a higher risk, which is now identified on the label.

Dr. Nicholas LaRocca, VP of Health Care Delivery and Policy Research at the National MS Society, said: "This label change marks an important advance in assisting people with MS and their physicians to make better-informed decisions concerning the
challenges of balancing effectiveness with safety.

"We are encouraged by the proactive role that Biogen Idec and Elan are taking in addressing PML risk stratification."

JCV is a virus that causes PML, a devastating brain infection that often leads to death or severe disability. Patients receiving Tysabri who test positive for the anti-JCV antibody are at a higher risk of developing PML than those who are not.

Biogen Idec, and its development partner, Elan (NYSE:ELN), have developed an FDA-approved assay service to determine MS patients' anti-JCV antibody status. The assay will be exclusively offered by Quest Diagnostics (NYSE:DGX).

Biogen Idec CEO Dr. George Scangos commented: "Tysabri has benefited thousands of patients worldwide who are living with multiple sclerosis, an often devastating disease affecting people in the prime of their lives.

"Biogen Idec and Elan's use of novel research and scientific expertise has allowed us to gain a better understanding of the benefit-risk profile for Tysabri.

"Our development of the risk stratification algorithm and subsequent efforts to support the commercial availability of anti-JCV antibody testing reflect our commitment to providing patients and their physicians with additional guidance to help them make more personalized treatment decisions."

Tysabri is already approved in over 65 countries, including in the U.S. as a monotherapy for relapsing forms of MS, and in the EU for highly active relapsing-remitting MS.

The U.S. label change follows the approval of a similar change in the EU, where about 59,000 anti-JCV antibody status tests have been performed during the third quarter of 2011 alone.

In premarket trading on Monday, Biogen Idec shares rose 0.3 percent to $118.50, as of 8:53 am EDT. In 2011, the company’s stock gained 64.13 percent.

View full BIIB profile View Profile

Biogen Inc Timeline

Related Articles

researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use